Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.54 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.46 |
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6384034 | 0.79 | PIN1 (0.38) | VCAM1ALDH1A1MAPTLMNAPIN1 | |
| SCHEMBL29951203 | 0.79 | XDH (0.46) | VCAM1XDHALDH5A1ABATALDH3A1 | |
| SCHEMBL27823778 | 0.79 | XDH (0.46) | VCAM1XDHALDH5A1ABATALDH3A1 | |
| SCHEMBL29956980 | 0.79 | XDH (0.54) | VCAM1XDHALDH5A1ABATALDH3A1 | |
| SCHEMBL18158923 | 0.78 | VCAM1 (0.46) | VCAM1XDHALDH5A1ABATALDH3A1 | |
| SCHEMBL801576 | 0.78 | VCAM1 (0.39) | VCAM1XDHALDH5A1ABATALDH1A1 | |
| SCHEMBL113455 | 0.77 | MAPK1 (0.44) | VCAM1ALDH1A1PIN1TSHRMAPK1 | |
| SCHEMBL29445407 | 0.77 | MAPK1 (0.44) | VCAM1ALDH1A1PIN1TSHRMAPK1 | |
| SCHEMBL985995 | 0.76 | AHR (0.51) | ALDH1A1MAPTLMNAHPGDHTT | |
| SCHEMBL29780392 | 0.76 | AHR (0.51) | ALDH1A1MAPTLMNAHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
| CN-1165535-C | Imidazo pyridine derivatives which inhibit gastric acid secretion | — | 2004-09-08 | — | — | CN | disclosed |
| CN-1307577-A | Imidazo pyridine derivatives which inhibit gastric acid secretion | ASTRA ZENECA AKTIEBOLAG (SE) | 2001-08-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | VCAM1 4723/4885XDH 70/4885ALDH5A1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.